JMJoshua Meyers

Joshua Meyers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joshua Meyers has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FragGT: Fragment-based evolutionary molecule generation with gene types

    by Joshua Meyers, Nathan Brown

    De novo molecular design is effective for optimizing compounds with desirable properties in drug discovery. In the realm of chemoinformatics, population-based evolutionary approaches have been known for over a decade including those that use retrosynthetically inspired fragment-based workflows to to balance the generation of synthesizable molecules with a sufficiently expressive molecular generator. We describe FragGT, a fragment-based de novo molecular design approach that uses an evolutionary algorithm to optimize molecules towards an objective function. We rely on the concept of gene types to hop between related molecular fragments where a fragment's gene type is defined by the nature of its connections to adjacent groups. We show that this simple approach achieves competitive performance on the GuacaMol benchmark suite with a low computational cost and the additional benefits of transparency and practicality.


  • Top Cited Papers
    Open Access

    De novo molecular design and generative models

    by Joshua Meyers, Benedek Fabian, Nathan Brown


  • Open Access

    DeeplyTough: Learning Structural Comparison of Protein Binding Sites

    by Martin Simonovsky, Joshua Meyers

    Protein pocket matching, or binding site comparison, is of importance in drug discovery. Identification of similar binding pockets can help guide efforts for hit finding, understanding polypharmacology and characterization of protein function. The design of pocket matching methods has traditionally involved much intuition, and has employed a broad variety of algorithms and representations of the input protein structures. We regard the high heterogeneity of past work and the recent availability of large-scale benchmarks as an indicator that a data-driven approach may provide a new perspective. We propose DeeplyTough, a convolutional neural network that encodes a three-dimensional representation of protein pockets into descriptor vectors that may be compared efficiently in an alignment-free manner by computing pairwise Euclidean distances. The network is trained with supervision: (i) to provide similar pockets with similar descriptors, (ii) to separate the descriptors of dissimilar pockets by a minimum margin, and (iii) to achieve robustness to nuisance variations. We evaluate our method using three large-scale benchmark datasets, on which it demonstrates excellent performance for held-out data coming from the training distribution and competitive performance when the trained network is required to generalize to datasets constructed independently. DeeplyTough is available at https://github.com/BenevolentAI/DeeplyTough.


  • Open Access

    DeeplyTough: Learning Structural Comparison of Protein Binding Sites

    by Martin Simonovsky, Joshua Meyers

    Motivation: Protein binding site comparison (pocket matching) is of importance in drug discovery. Identification of similar binding sites can help guide efforts for hit finding, understanding polypharmacology and characterization of protein function. The design of pocket matching methods has traditionally involved much intuition, and has employed a broad variety of algorithms and representations of the input protein structures. We regard the high heterogeneity of past work and the recent availability of large-scale benchmarks as an indicator that a data-driven approach may provide a new perspective. Results: We propose DeeplyTough, a convolutional neural network that encodes a three-dimensional representation of protein binding sites into descriptor vectors that may be compared efficiently in an alignment-free manner by computing pairwise Euclidean distances. The network is trained with supervision: (i) to provide similar pockets with similar descriptors, (ii) to separate the descriptors of dissimilar pockets by a minimum margin, and (iii) to achieve robustness to nuisance variations. We evaluate our method using three large-scale benchmark datasets, on which it demonstrates excellent performance for held-out data coming from the training distribution and competitive performance when the trained network is required to generalize to datasets constructed independently. Availability: https://github.com/BenevolentAI/DeeplyTough Contact: martin.simonovsky@enpc.fr , joshua.meyers@benevolent.ai


  • Open Access

    Privileged Structures and Polypharmacology within and between Protein Families

    by Joshua Meyers, Nicola E. A. Chessum, Salyha Ali, N. Yi Mok, Birgit Wilding, A. Elisa Pasqua, Martin Rowlands, Michael J. Tucker, Lindsay E. Evans, Carl S. Rye, et al.

    Polypharmacology is often a key contributor to the efficacy of a drug, but is also a potential risk. We investigated two hits discovered via a cell-based phenotypic screen, the CDK9 inhibitor CCT250006 (1) and the pirin ligand CCT245232 (2), to establish methodology to elucidate their secondary protein targets. Using computational pocket-based analysis, we discovered intrafamily polypharmacology for our kinase inhibitor, despite little overall sequence identity. The interfamily polypharmacology of 2 with B-Raf was used to discover a novel pirin ligand from a very small but privileged compound library despite no apparent ligand or binding site similarity. Our data demonstrates that in areas of drug discovery where intrafamily polypharmacology is often an issue, ligand dissimilarity cannot necessarily be used to assume different off-target profiles and that understanding interfamily polypharmacology will be important in the future to reduce the risk of idiopathic toxicity and in the design of screening libraries.


  • Open Access

    Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89

    by L. Allott, C. Da Pieve, J. Meyers, T. Spinks, D. M. Ciobota, G. Kramer-Marek, G. Smith

    The future of 89Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO).


  • Open Access

    Mapping the 3D structures of small molecule binding sites

    by Joshua Meyers, Nathan Brown, Julian Blagg

    Analysis of the 3D structures of protein–ligand binding sites can provide valuable insights for drug discovery. Binding site comparison (BSC) studies can be employed to elucidate the function of orphan proteins or to predict the potential for polypharmacology. Many previous binding site analyses only consider binding sites surrounding an experimentally observed bound ligand. To encompass potential protein–ligand binding sites that do not have ligands known to bind, we have incorporated fpocket cavity detection software and assessed the impact of this inclusion on BSC performance. Using fpocket, we generated a database of ligand-independent potential binding sites and applied the BSC tool, SiteHopper, to analyze similarity relationships between protein binding sites. We developed a method for clustering potential binding sites using a curated dataset of structures for six therapeutically relevant proteins from diverse protein classes in the protein data bank. Two clustering methods were explored; hierarchical clustering and a density-based method adept at excluding noise and outliers from a dataset. We introduce circular plots to visualize binding site structure space. From the datasets analyzed in this study, we highlight a structural relationship between binding sites of cationic trypsin and prothrombin, protein targets known to bind structurally similar small molecules, exemplifying the potential utility of objectively and holistically mapping binding site space from the structural proteome. We present a workflow for the objective mapping of potential protein–ligand binding sites derived from the currently available structural proteome. We show that ligand-independent binding site detection tools can be introduced without excessive penalty on BSC performance. Clustering combined with intuitive visualization tools can be applied to map relationships between the 3D structures of protein binding sites.


  • Open Access

    On the Origins of Three-Dimensionality in Drug-Like Molecules

    by Joshua Meyers, Michael Carter, N Yi Mok, Nathan Brown

    Aim: Many medicinal chemistry-relevant structures and core scaffolds tend toward geometric planarity, which hampers the optimization of physicochemical properties desirable in drug-like molecules. ...